GEF‐H1 over‐expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling
Ibis K.-C. Cheng(Chinese University of Hong Kong), Nathalie Wong(Chinese University of Hong Kong), Ka‐Fai To(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Bruce CK Tsang(Chinese University of Hong Kong), Anthony W.H. Chan(Chinese University of Hong Kong), Arthur K. Ching(Chinese University of Hong Kong), Keng Po Lai(Department of Health)
Cited by 45
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
|Proceedings of the National Academy of Sciences|2015|818
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
|Proceedings of the National Academy of Sciences|2015|770